Evidence map›Paper›PMID 35779777›Full record

ArticleNeurobiology of disease2022

Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.

Athanasios S Alexandris, Jiwon Ryu, Labchan Rajbhandari, Robert Harlan, James McKenney, Yiqing Wang, Susan Aja, David Graham, Arun Venkatesan, Vassilis E Koliatsos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. The role of NADnpj metabolic health and disease · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. NADAntioxidants & redox signaling · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Athanasios S AlexandrisDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: a.alexandris@jhmi.edu.
Jiwon RyuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Labchan RajbhandariDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert HarlanThe Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.
James McKenneyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yiqing WangDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Susan AjaThe Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.
David GrahamThe Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.
Arun VenkatesanDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Vassilis E KoliatsosDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: koliat@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins All Children's Hospital · USJohns Hopkins University · US

Funding

Traumatic axonal injury in the visual system: role of dual leucine zipper kinaseR01EY028039 · NEI · JOHNS HOPKINS UNIVERSITY · PI KOLIATSOS, VASSILIS E, ZACK, DONALD J. · 2017 to 2021
$2.9M
Traumatic Axonopathy in the CNS as Wallerian degenerationR01NS114397 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOLIATSOS, VASSILIS E · 2021 to 2025
$2.4M
NEI NIH HHS R01 EY028039NINDS NIH HHS R01 NS114397
6 · The paper itself

Abstract

Wallerian degeneration (WD) is a conserved axonal self-destruction program implicated in several neurological diseases. WD is driven by the degradation of the NAD

Indexed as

Nicotinamide-Nucleotide AdenylyltransferaseWallerian DegenerationAnimalsArmadillo Domain ProteinsAxonsCytoskeletal ProteinsHumansMammalsNADNerve DegenerationNicotinamide PhosphoribosyltransferaseProtein Kinase InhibitorsArmadillo Domain ProteinsCytoskeletal ProteinsNADNicotinamide-Nucleotide AdenylyltransferaseNicotinamide PhosphoribosyltransferaseProtein Kinase InhibitorsNAD(+)NeurodegenerationNeuropathyNiacinNMNAT2SARM1

Identifiers

PMID35779777
PMCPMC10621467
OpenAlexW4283716948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.